Lexicon Pharmaceuticals Inc (NAS:LXRX)
$ 0.7734 -0.01075 (-1.37%) Market Cap: 279.58 Mil Enterprise Value: 122.41 Mil PE Ratio: 0 PB Ratio: 1.57 GF Score: 44/100

Lexicon Pharmaceuticals Inc LX9211 Call Transcript

Nov 14, 2022 / 10:00PM GMT
Release Date Price: $2.33 (-1.69%)
Operator

Good afternoon, ladies and gentlemen, and welcome to the Lexicon Pharmaceuticals Inc. full stated results from RELIEF-DPN-1. (Operator Instructions) This call is being recorded on November 14, 2022.

I would now like to turn the conference over to Mike Kelly. Please go ahead, sir.

Mike Kelly

Thank you, Andrew. Good afternoon, and welcome to the Lexicon Pharmaceuticals conference call. Joining me today are Lonnel Coats, Lexicon's Chief Executive Officer; Jeff Wade, Lexicon's President and Chief Financial Officer; Dr. Craig Granowitz, Lexicon's Senior Vice President and Chief Medical Officer; and Dr. Anand Patel, Chief Medical Officer at Conquest Research.

Earlier today, Lexicon issued a press release reporting full results from the RELIEF-DPN-1 Phase II proof-of-concept study of LX9211 in painful diabetic neuropathy, which was also presented at the 16th Annual Pain Therapeutics Summit by Dr. Patel. Copy of that press release as well as a webcast of this call and the slide presentation is available on our website at

Already have an account? Log in
Get the full story
Access to All Earning Calls and Stock Analysis
30-Year Financial on one screen
All-in-one Stock Screener with unlimited filters
Customizable Stock Dashboard
Real Time Insider Trading Transactions
8,000+ Institutional investors’ 13F holdings
Powerful Excel Add-in and Google sheets Add-on
All data downloadable
Quick customer support
And much more...
30-Day 100% money back guarantee
You are not charged until the trial ends. Subscription fee may be tax deductible.
Excellent
4.6 out of 5 Trustpilot